<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02799095</url>
  </required_header>
  <id_info>
    <org_study_id>ALK4230-A101</org_study_id>
    <nct_id>NCT02799095</nct_id>
  </id_info>
  <brief_title>A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors</brief_title>
  <official_title>A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkermes, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkermes, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To better understand the safety and tolerability of ALKS 4230 in humans&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate the safety and tolerability of ALKS 4230, determine the recommended Phase 2&#xD;
      dose (RP2D) and assess anti-tumor activity in Monotherapy and ALKS 4230 in Combination with&#xD;
      pembrolizumab.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterization of adverse events (AEs) and dose-limiting toxicities (DLT) in study Part A</measure>
    <time_frame>From time of initiation of therapy until 30 days after last dose of study drug, assessed up to 24 months</time_frame>
    <description>Incidence of AEs that are both serious and drug-related</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of drug-related AEs in study Part B</measure>
    <time_frame>From time of initiation of therapy until 30 days after last dose of study drug, assessed up to 24 months</time_frame>
    <description>Incidence of AEs that are drug-related</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate (ORR) of ALKS 4230 monotherapy in patients with melanoma or renal cell carcinoma (Part B) and in combination with pembrolizumab in patients with advanced solid tumors (Part C)</measure>
    <time_frame>From time of initiation of therapy until 30 days after last dose of study drug assessed up to 24 months</time_frame>
    <description>Proportion of patients with the confirmed overall response of complete response or partial response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>From time of initiation of therapy until the date of first documented tumor progression, assessed up to 24 months</time_frame>
    <description>Proportion of subjects with objective evidence of CR, PR, or Stable Disease (SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response in subjects with CR/iCR or PR/iPR</measure>
    <time_frame>From time of initiation of therapy until the date of first documented tumor progression, assessed up to 24 months</time_frame>
    <description>Time from the first documentation of response (CR/iCR or PR/iPR) to the first documentation of objective tumor progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of ALKS 4230 will be determined at various time points</measure>
    <time_frame>From time of initiation of therapy until the last treatment cycle, assessed up to 24 months</time_frame>
    <description>Concentration vs time and standard pharmacokinetic (PK) parameters will be summarized by dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum will be assayed for the presence of anti-ALKS 4230 antibodies</measure>
    <time_frame>From time of initiation of therapy until the last treatment cycle, assessed up to 24 months</time_frame>
    <description>Results will be summarized by dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunophenotyping of peripheral blood mononuclear cells will be performed by flow cytometry at various time points</measure>
    <time_frame>From time of initiation of therapy until the last treatment cycle, assessed up to 24 months</time_frame>
    <description>Results will be summarized by dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of proinflammatory cytokines will be assessed using a multiplex method at various time points</measure>
    <time_frame>From time of initiation of therapy during the first two treatment cycles, assessed up to 2 months</time_frame>
    <description>Results will be summarized by dose level</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">243</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>ALKS 4230</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ALKS 4230 + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALKS 4230</intervention_name>
    <description>Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days followed by an off-treatment period</description>
    <arm_group_label>ALKS 4230</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALKS 4230 + pembrolizumab</intervention_name>
    <description>IV infusion of ALKS 4230 over 30 minutes given daily for 5 consecutive days followed by an off-treatment period; pembrolizumab administered IV once with ALKS 4230 on the first day of each cycle</description>
    <arm_group_label>ALKS 4230 + pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For Part A, the subject has histological or cytological evidence of a solid tumor; for&#xD;
             Part B, the subject has a diagnosis of melanoma or renal cell carcinoma&#xD;
&#xD;
          -  All subjects must have advanced solid tumors that have returned after treatment with&#xD;
             established approved therapies or be intolerant of established therapies&#xD;
&#xD;
          -  Subjects enrolled in Part B or Part C must have at least 1 lesion that may qualify as&#xD;
             a target lesion&#xD;
&#xD;
          -  Subject can move around on their own, has an Eastern Cooperative Oncology Group (ECOG)&#xD;
             performance status of 0 or 1, and has an estimated life expectancy of at least 3&#xD;
             months&#xD;
&#xD;
          -  Subject must have adequate hematologic reserve&#xD;
&#xD;
          -  Subjects must have adequate liver function&#xD;
&#xD;
          -  Subjects must have adequate kidney function&#xD;
&#xD;
          -  Subjects must be recovered from the effects of any prior chemotherapy, immunotherapy,&#xD;
             other prior systemic anticancer therapy, radiotherapy or surgery&#xD;
&#xD;
          -  Subjects who have received investigational agents must wait at least 4 weeks&#xD;
&#xD;
          -  Females of childbearing potential must have a negative pregnancy test within 7 days of&#xD;
             the start of treatment and on Day 1 before the first dose is administered. A female&#xD;
             not of childbearing potential is one who has undergone bilateral oophorectomies or who&#xD;
             is postmenopausal, defined as &gt;45 years of age and without a menstrual period for 12&#xD;
             consecutive months&#xD;
&#xD;
          -  Meets contraceptive requirements defined in the protocol&#xD;
&#xD;
          -  Additional criteria may apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is currently pregnant or breastfeeding, or is planning to become pregnant&#xD;
             during the study&#xD;
&#xD;
          -  Subjects with an active infection or with a fever &gt;/= 38.5 degrees C within 3 days of&#xD;
             the first scheduled day of dosing for Cycle 1&#xD;
&#xD;
          -  Subjects with active or symptomatic central nervous system metastases are excluded.&#xD;
             Subjects with central nervous system metastases are eligible for the study if the&#xD;
             metastases have been treated by surgery and/or radiation therapy, the subject is off&#xD;
             corticosteroids for at least 2 weeks and the subject is neurologically stable&#xD;
&#xD;
          -  Subjects have a mean QT interval corrected by the Fridericia Correction formula value&#xD;
             of &gt;470 msec (in females) or &gt;450 msec (in males)&#xD;
&#xD;
          -  Subjects with known hypersensitivity to any components of ALKS 4230&#xD;
&#xD;
          -  Subjects with known hypersensitivity to any components of pembrolizumab (for patients&#xD;
             in combination arm only)&#xD;
&#xD;
          -  Subjects who require pharmacologic doses of corticosteroids; replacement doses,&#xD;
             topical, ophthalmologic, and inhalational steroids are permitted&#xD;
&#xD;
          -  Subjects who developed autoimmune disorders while on prior immunotherapy, including&#xD;
             pneumonitis, nephritis, and neuropathy&#xD;
&#xD;
          -  Subjects with any other concurrent uncontrolled illness, including mental illness or&#xD;
             substance abuse, which may interfere with the ability of the subject to cooperate and&#xD;
             participate in the study&#xD;
&#xD;
          -  The subject is known to be positive for human immunodeficiency virus (HIV), hepatitis&#xD;
             B or C, or active tuberculosis, or has a known history of tuberculosis&#xD;
&#xD;
          -  Subjects with dyspnea at rest of requiring oxygen therapy&#xD;
&#xD;
          -  Subjects active autoimmune disease requiring systemic treatment within the past 30&#xD;
             days&#xD;
&#xD;
          -  Subjects who received radiotherapy within the last 4 weeks before start of study&#xD;
             treatment administration with the exception of limited field palliative radiotherapy&#xD;
&#xD;
          -  Subjects who have received systemic immunomodulatory agents within 28 days prior to&#xD;
             C1D1.&#xD;
&#xD;
          -  Subjects who have received administration of a live, attenuated vaccine within 4 weeks&#xD;
             of Cycle 1, Day1.&#xD;
&#xD;
          -  Prior solid organ and/or non-autologous hematopoietic stem cell or bone marrow&#xD;
             transplant recipients&#xD;
&#xD;
          -  Subjects who have received prior IL-2 based or IL-15 based cytokine therapy&#xD;
&#xD;
          -  Additional criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Alkermes, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <zip>34952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>47201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investgational Site</name>
      <address>
        <city>Albury</city>
        <state>New South Wales</state>
        <zip>2640</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Brussels</city>
        <state>MO</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Kortrijk</city>
        <state>West-Vlaanderen</state>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Daejeon</city>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Skorzewo</city>
        <state>Poznan</state>
        <zip>60-185</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 1, 2016</study_first_submitted>
  <study_first_submitted_qc>June 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2016</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>IL-2</keyword>
  <keyword>Interleukin-2</keyword>
  <keyword>Solid tumors</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Renal cell carcinoma</keyword>
  <keyword>Non-small-cell lung cancer</keyword>
  <keyword>Squamous cell carcinoma of the head and neck</keyword>
  <keyword>in combination with pembrolizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>At this time, IPD sharing has not been defined and/or decided if it will be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

